Sanofi Selects Recursion Treatment for Inflammatory Diseases
Sanofi selected an experimental treatment developed through its multi-program research collaboration with Recursion Pharmaceuticals. Recursion shares rose more than 16% on Thursday; the update also coincided with a $200 million stock offering.
Shares of Recursion Pharmaceuticals (RXRX) surged more than 16% on Thursday after French drugmaker Sanofi (SNY) selected an experimental treatment for inflammatory diseases developed through their multi-program research collaboration.The update comes alongside a $200 million stock offering that Rec…